{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:12:51Z","timestamp":1782400371332,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.esmoop.2024.103661","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T16:43:54Z","timestamp":1722617034000},"page":"103661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study"],"prefix":"10.1016","volume":"9","author":[{"given":"E.","family":"Chatziioannou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M. Serna","family":"Higuita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kreft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kandolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Dujovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Marquez-Rodas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.F.P.","family":"Fortuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"N\u00fcbling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Niessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Forschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mirjana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Eigentler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Flatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Sinnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2024.103661_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jid.2020.03.943","article-title":"Treatment of advanced melanoma in 2020 and beyond","volume":"141","author":"Jenkins","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103661_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.esmoop.2024.103661_bib3","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.2217\/fon-2021-1536","article-title":"Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy","volume":"18","author":"Atkins","year":"2022","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103661_bib4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103661_bib5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial\u2014ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2024.103661_bib6","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103661_bib7","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103661_bib8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"57","key":"10.1016\/j.esmoop.2024.103661_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd5515","article-title":"Bispecific antibodies targeting mutant RAS neoantigens","volume":"6","author":"Douglass","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.esmoop.2024.103661_bib10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103661_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40257-023-00775-7","article-title":"Features and long-term outcomes of stage IV melanoma patients achieving complete response under anti-PD-1-based immunotherapy","volume":"24","author":"Chatziioannou","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.esmoop.2024.103661_bib12","doi-asserted-by":"crossref","first-page":"S734","DOI":"10.1016\/j.annonc.2020.08.1206","article-title":"1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone","volume":"31","author":"Robert","year":"2020","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2024.103661_bib13","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","article-title":"Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma","volume":"36","author":"Robert","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103661_bib14","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41467-020-14987-6","article-title":"Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours","volume":"11","author":"Brenner","year":"2020","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103661_bib15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103661_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103661_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.103661_bib18","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1214\/08-AOAS169","article-title":"Random survival forests","volume":"2","author":"Ishwaran","year":"2008","journal-title":"Ann Appl Stat"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103661_bib19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12874-021-01375-x","article-title":"Random survival forests for dynamic predictions of a time-to-event outcome using a longitudinal biomarker","volume":"21","author":"Pickett","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.esmoop.2024.103661_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.551420","article-title":"A\u00a0comparison study of machine learning (random survival forest) and classic statistic (Cox proportional hazards) for predicting progression in high-grade glioma after proton and carbon ion radiotherapy","volume":"10","author":"Qiu","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103661_bib21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ejcts\/ezy403","article-title":"Statistical primer: multivariable regression considerations and pitfalls","volume":"55","author":"Grant","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103661_bib22","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S1470-2045(14)71116-7","article-title":"Nomograms in oncology: more than meets the eye","volume":"16","author":"Balachandran","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103661_bib23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41416-018-0167-x","article-title":"S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies","volume":"119","author":"Wagner","year":"2018","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103661_bib24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy","volume":"126","author":"Pires da Silva","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103661_bib25","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103661_bib26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2022.08.034","article-title":"High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy","volume":"177","author":"Dercle","year":"2022","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103661_bib27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/bjc.2012.306","article-title":"Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis","volume":"107","author":"Weide","year":"2012","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1016\/j.esmoop.2024.103661_bib28","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025318","article-title":"Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1\/PD-L1 therapy: a meta-analysis","volume":"100","author":"Xu","year":"2021","journal-title":"Medicine"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103661_bib29","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103661_bib30","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/bjc.2015.467","article-title":"Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma","volume":"114","author":"Diem","year":"2016","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103661_bib31","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41571-022-00686-2","article-title":"The multiple roles of LDH in cancer","volume":"19","author":"Claps","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103661_bib32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.intimp.2018.01.019","article-title":"Platelet-to-lymphocyte ratio in peripheral blood: a novel independent prognostic factor in patients with melanoma","volume":"56","author":"Qi","year":"2018","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103661_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101119","article-title":"Prognostic value of PLR in various cancers: a meta-analysis","volume":"9","author":"Zhou","year":"2014","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103661_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-021-00571-6","article-title":"Neutrophils in cancer: heterogeneous and multifaceted","volume":"22","author":"Hedrick","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103661_bib35","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12916-020-01817-1","article-title":"Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies","volume":"18","author":"Cupp","year":"2020","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103661_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56218-z","article-title":"Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer","volume":"9","author":"Howard","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103661_bib37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/CMR.0b013e3283350554","article-title":"Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours","volume":"20","author":"Sviatoha","year":"2010","journal-title":"Melanoma Res"},{"issue":"18","key":"10.1016\/j.esmoop.2024.103661_bib38","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1158\/0008-5472.CAN-22-0363","article-title":"Mapping the immune landscape in metastatic melanoma reveals localized cell-cell interactions that predict immunotherapy response","volume":"82","author":"Antoranz","year":"2022","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103661_bib39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/1078-0432.CCR-21-1193","article-title":"The liver-immunity nexus and cancer immunotherapy","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103661_bib40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103661_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0448","article-title":"Outcomes among patients with or without obesity and with cancer following treatment with immune checkpoint blockade","volume":"5","author":"Yoo","year":"2022","journal-title":"JAMA Network Open"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103661_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225253","article-title":"Visualising statistical models using dynamic nomograms","volume":"14","author":"Jalali","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103661_bib43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12967-022-03359-x","article-title":"Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma","volume":"20","author":"Guida","year":"2022","journal-title":"J\u00a0Transl Med"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103661_bib44","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1186\/s12885-020-07700-9","article-title":"Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis","volume":"20","author":"Kim","year":"2020","journal-title":"BMC Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:07:15Z","timestamp":1737331635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924014303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2059702924014303"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103661","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103661"}}